Table 1.
Characteristics of included studies.
| Author and Publication year | Sample size (E) | Sample size (C) | Intervention (E) | Intervention (C) | Dosage of CDDP | Duration of CDDP | Dosage of ID or IN | Duration of ID or IN | Outcomes |
|---|---|---|---|---|---|---|---|---|---|
| Liu 1997 | 62 | 30 | CDDP | ID | 810 mg/day | 6 weeks | 30 mg/day | 6 weeks | AR |
| Zhou 1998 | 120 | 60 | CDDP | IN | 810 mg/day | 2 months | 30 mg/day | 2 months | ERSI,MERSI,EREI, MEREI, AR |
| Ding 1999 | 52 | 50 | CDDP | ID | 810 mg/day | 2 months | 30 mg/day | 2 months | ERSI,MERSI, AR |
| Zhang 1999 | 69 | 64 | CDDP | ID | 810 mg/day | 30 days | 30 mg/day | 30 days | ERSI,MERSI, AR |
| Gao 2000 | 60 | 60 | CDDP | ID | 810 mg/day | 8 weeks | 30 mg/day | 8 weeks | ERSI,MERSI,EREI, MEREI,AR |
| Tan 2001 | 40 | 40 | CDDP | ID | 810 mg/day | 4 weeks | 30 mg/day | 4 weeks | ERSI,MERSI,EREI, MEREI |
| Lu 2001 | 60 | 60 | CDDP | ID | 810 mg/day | 8 weeks | 30 mg/day | 8 weeks | ERSI,MERSI,EREI, MEREI |
| Zhu 2001 | 80 | 80 | CDDP | ID | 810 mg/day | 8 weeks | 30 mg/day | 8 weeks | ERSI,MERSI,EREI, MEREI |
| Yang 2001 | 43 | 40 | CDDP | ID | 810 mg/day | 8 weeks | 30 mg/day | 8 weeks | ERSI,MERSI,EREI, MEREI, AR |
| Shi 2001 | 102 | 51 | CDDP | ID | 810 mg/day | 4 weeks | 30 mg/day | 4 weeks | ERSI,MERSI, AR |
| Dong 2001 | 30 | 30 | CDDP | ID | 810 mg/day | 4 weeks | 30 mg/day | 4 weeks | ERSI,MERSI,EREI, MEREI,AR |
| Xue 2001 | 102 | 90 | CDDP | ID | 810 mg/day | 45 days | 30 mg/day | 45 days | ERSI,MERSI,EREI, MEREI,AR |
| Guo 2001 | 25 | 25 | CDDP | ID | 810 mg/day | 8 weeks | 30 mg/day | 8 weeks | ERSI,MERSI,EREI, MEREI |
| Deng 2002 | 56 | 30 | CDDP | ID | 810 mg/day | 8 weeks | 30 mg/day | 8 weeks | ERSI,MERSI, AR |
| Yao 2002a | 50 | 50 | CDDP | ID | 810 mg/day | 8 weeks | 30 mg/day | 8 weeks | ERSI,MERSI,EREI, MEREI |
| Yao 2002b | 50 | 50 | CDDP | ID | 810 mg/day | 4 weeks | 30 mg/day | 4 weeks | AR |
| Wang 2003 | 52 | 50 | CDDP | ID | 810 mg/day | 2 months | 30 mg/day | 2 months | ERSI,MERSI,EREI, MEREI, AR |
| Chu 2003 | 35 | 32 | CDDP | ID | 810 mg/day | 60 days | 30 mg/day | 60 days | ERSI,MERSI,EREI, MEREI |
| Huang 2004 | 40 | 38 | CDDP | ID | 810 mg/day | 2 months | 30 mg/day | 2 months | AR |
| Li 2005 | 70 | 60 | CDDP | IN | 810 mg/day | 6 weeks | 30 mg/day | 6 weeks | EREI,MEREI, AR |
| Li 2006 | 56 | 50 | CDDP | IN | 810 mg/day | 6 weeks | 30 mg/day | 6 weeks | ERSI,MERSI, AR |
| Chi 2007 | 120 | 114 | CDDP | ID | 810 mg/day | 4 weeks | 30 mg/day | 4 weeks | ERSI,MERSI,EREI, MEREI,AR |
| Yue 2008 | 55 | 53 | CDDP | IN | 810 mg/day | 1 month | 30 mg/day | 1 month | ERSI,MERSI, AR |
| Pan 2008 | 50 | 30 | CDDP | ID | 810 mg/day | 6 weeks | 30 mg/day | 6 weeks | ERSI,MERSI, AR |
| Luo 2008 | 54 | 52 | CDDP | IN | 810 mg/day | 1 month | 30 mg/day | 1 month | ERSI,MERSI, AR |
| Wang 2009 | 29 | 28 | CDDP | ID | 810 mg/day | 6 weeks | 30 mg/day | 6 weeks | AR |
| Zhang 2009 | 30 | 30 | CDDP | ID | 810 mg/day | 8 weeks | 30 mg/day | 8 weeks | ERSI,MERSI, EREI, MEREI,AR |
| Gong 2013 | 60 | 60 | CDDP | IN | 810 mg/day | 12 weeks | 30 mg/day | 12 weeks | AR |
| Shao 2013 | 66 | 60 | CDDP | IN | 810 mg/day | 1 month | 30 mg/day | 1 month | AR |
E, Experimental group; C, Control group; CDDP, compound danshen dripping pills; ID, isosorbide dinitrate; IN, isosorbide nitrate; ERSI, Effective rate in symptom improvement; MERSI, Markedly effective rate in symptom improvement; EREI, Effective rate in ECG improvement; MEREI, Markedly effective rate in ECG improvement; AR, Adverse reaction.